MARK LIEVONEN, PRESIDENT OF SANOFI PASTEUR LIMITED, RECEIVES LIFETIME ACHIEVEMENT AWARD FROM LIFE SCIENCES ONTARIO

Lievonen joins prestigious group of award winners for leadership and contributions to the development of the Life Sciences Sector in Canada

TORONTO, February 27, 2014 – Mark Lievonen, President of Sanofi Pasteur Limited, the Canadian vaccine division of the Sanofi Group, has been awarded the Lifetime Achievement Award from Life Sciences Ontario (LSO).  This award is in recognition of Mr. Lievonen’s exceptional leadership and contributions to the development of the Life Sciences sector in Canada, his commitment to the community and his passion for improving the quality of life for Canadians.

Mr. Lievonen received the award at the annual Life Sciences Ontario’s Awards Gala on February 26 from Paul Lucas, President and Chair of LSO. 

Paul Lucas, President and Chair of Life Sciences Ontario; Norm Kelly, Deputy Mayor of Toronto; Mark Lievonen, President and CEO of Sanofi Pasteur; Hon. Reza Moridi, Minister of Research and Innovation; Jason Field, Executive Director of Life Sciences Ontario

“As the life sciences industry in Ontario continues to evolve, it’s important to celebrate people who have made meaningful contributions to the growth and prosperity of the sector,” said Paul Lucas. “Mark’s career is marked by outstanding achievements, unwavering dedication and commitment to the life sciences community, as evidenced by his leadership at Sanofi Pasteur, volunteer activities and supporting the advancement of the next generation of scientists.” 

LSO’s Lifetime Achievement Award is bestowed to a highly respected leader who has inspired and led the community to imagine a bigger future in life sciences. Previous award winners include Dr. Calvin Stiller, a public policy champion instrumental in founding the Robarts Research Institute in London, the Ontario Institute for Cancer Research and MaRS, and Dr. Henry Friesen, a distinguished Canadian scientist, past president of the Medical Research Council of Canada, past president of the National Cancer Institute of Canada and founding chair of Genome Canada.

“As Sanofi Pasteur approaches its 100th anniversary in Canada, I am proud to represent an organization that has contributed to the growth and sustainability of Ontario’s thriving biotechnology sector,” said Mr. Lievonen. “Throughout my career, I have aspired to create a meaningful impact by stimulating innovation and enhancing Canadian competitiveness and productivity. I am humbled to be joining the ranks of esteemed leaders.”

Mr. Lievonen joined Sanofi Pasteur (formerly known as Connaught Laboratories) in 1983 and was named President in 1999. Over the last three decades, he has helped to transform a vital manufacturing and R&D organization in Toronto into a global, billion dollar biotechnology enterprise, which stands as a symbol of Canadian talent, innovation and R&D excellence. Today, Sanofi Pasteur Limited employs over 1200 highly-skilled and passionate people. The Toronto facility manufactures over 50 million doses of vaccines, preventing disease for millions of people in Canada and around the world.

Deeply committed to building a sustainable healthcare system in Canada, Mr. Lievonen is a director of Oncolytics Biotech Inc., and was recently appointed Chair, Research-Based Pharmaceutical Companies (Rx&D). He is the Vice Chair of Ontario Institute for Cancer Research, and serves on the boards of Public Policy Forum, York University, BIOTECanada, and Markham Stouffville Hospital Foundation.  In 1993, he spearheaded the creation of Canada’s only mentored science competition, the Sanofi BioGENEius Challenge Canada (SBCC), to foster biotechnology talent among high school students.

To see Mr. Lievonen’s complete biography click here.

 

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi’s strengths in the healthcare sector include seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi companies in Canada include Sanofi-Aventis Canada Inc. (Pharmaceuticals), Sanofi Pasteur (Vaccines), Sanofi Consumer Health (Health and Beauty), Genzyme (Rare Diseases) and Merial (Animal Health). Together, the Sanofi Group employs more than 1,700 people, mainly in the greater Montreal and Toronto areas. In 2012, Sanofi companies invested $123 million in R&D in Canada, creating jobs and economic activities throughout the country.

 

-30-

Media Contacts:

Kara LATTA

CASACOM

klatta@casacom.ca

Tel: 416-944-2145